Liquidia Technologies (LQDA) Stock Price, News & Analysis

Company Overview

Liquidia Technologies is a clinical‐stage biopharmaceutical company focused on the development of precision medicines through its proprietary PRINT® (Particle Replication In Non‐wetting Templates) technology. The company applies its particle-engineering platform to design and manufacture inhaled and injectable formulations, aiming to address diseases with high unmet medical need. Liquidia’s lead programs target pulmonary arterial hypertension (PAH) and other respiratory conditions, leveraging its ability to precisely control particle size, shape and composition for optimal drug delivery.

The company’s most advanced product candidate is Tyvaso® DPI (LIQ861), a dry powder formulation of treprostinil for the treatment of PAH. Developed in collaboration with United Therapeutics Corporation, Tyvaso DPI is designed to offer patients an alternative to nebulized delivery, with the goal of improving convenience and adherence. In addition to PAH, Liquidia’s pipeline includes programs in acute and chronic pain, as well as emerging immunotherapy and vaccine applications that utilize the versatility of its PRINT technology.

Founded on work originating from the University of North Carolina at Chapel Hill, Liquidia Technologies was established to translate academic innovations in nanotechnology into therapeutic solutions. Since its inception, the company has expanded its capabilities in particle engineering, formulation development and clinical manufacturing. The PRINT platform has been applied across small molecules, biologics and combination products, positioning Liquidia as a partner of choice for companies seeking novel drug‐delivery solutions.

Headquartered in Research Triangle Park, North Carolina, Liquidia operates with a global outlook, engaging in strategic partnerships and clinical collaborations worldwide. Under the leadership of President and Chief Executive Officer Douglas Kajdasz and Chief Financial Officer Christine Bovis, the company continues to advance its pipeline through clinical trials and regulatory milestones. With a focus on innovation and patient-centric design, Liquidia aims to bring differentiated therapies to market for complex diseases.

Key Stats

• Today's Range: $14.42 to $15.25
• 50-Day Range: $12.00 to $19.30
• 52-Week Range: $8.26 to $19.41
• Volume: 785,316 shs
• Average Volume: 1.30 million shs
• Market Capitalization: $1.29 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.89
• Consensus Rating: Buy

Liquidia Technologies Stock Analysis - MarketRank™

Liquidia Technologies scored higher than 65% of companies evaluated by MarketBeat, and ranked 342nd out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Liquidia Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Liquidia Technologies has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Liquidia Technologies are expected to grow in the coming year, from ($1.51) to ($1.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Liquidia Technologies is -9.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Liquidia Technologies is -9.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Liquidia Technologies has a P/B Ratio of 16.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

33.98% of the float of Liquidia Technologies has been sold short.

Short Interest Ratio / Days to Cover

Liquidia Technologies has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Liquidia Technologies has recently increased by 9.49%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Liquidia Technologies does not currently pay a dividend.

Dividend Growth

Liquidia Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

33.98% of the float of Liquidia Technologies has been sold short.

Short Interest Ratio / Days to Cover

Liquidia Technologies has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Liquidia Technologies has recently increased by 9.49%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.21

News Sentiment

Liquidia Technologies has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Liquidia Technologies this week, compared to 6 articles on an average week.

Search Interest

Only 3 people have searched for LQDA on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Liquidia Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $842,992.00 in company stock.

Percentage Held by Insiders

30.10% of the stock of Liquidia Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.54% of the stock of Liquidia Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LQDA Stock Analysis - Frequently Asked Questions

How have LQDA shares performed this year?

Liquidia Technologies' stock was trading at $11.76 on January 1st, 2025. Since then, LQDA shares have increased by 26.9% and is now trading at $14.92.

How were Liquidia Technologies' earnings last quarter?

Liquidia Technologies, Inc. (NASDAQ:LQDA) issued its earnings results on Thursday, May, 8th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.03. The business earned $3.12 million during the quarter, compared to the consensus estimate of $3.23 million. Liquidia Technologies had a negative trailing twelve-month return on equity of 177.91% and a negative net margin of 903.80%.
Read the conference call transcript.

When did Liquidia Technologies IPO?

Liquidia Technologies (LQDA) raised $50 million in an initial public offering on Thursday, July 26th 2018. The company issued 4,500,000 shares at a price of $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are Liquidia Technologies' major shareholders?

Liquidia Technologies' top institutional shareholders include Sapient Capital LLC (0.09%), Whitcomb & Hess Inc. (0.03%), Ballentine Partners LLC (0.01%) and Significant Wealth Partners LLC (0.01%). Insiders that own company stock include Caligan Partners Lp, Roger Jeffs, Russell Schundler, Michael Kaseta, Rajeev Saggar, Scott Moomaw, Robert A Lippe, Jason Adair, Dana Boyle and Sarah Krepp.
View institutional ownership trends.

How do I buy shares of Liquidia Technologies?

Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Liquidia Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Liquidia Technologies investors own include JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Ford Motor (F), Predictive Oncology (POAI), Tesla (TSLA), Advanced Micro Devices (AMD) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/21/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LQDA
• CIK: 1819576
• Web: www.liquidia.com
• Phone: (919) 328-4400
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Liquidia Technologies: $26.89
• High Price Target: $37.00
• Low Price Target: $13.00
• Potential Upside/Downside: +84.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$130.39 million
• Net Margins: -903.80%
• Pretax Margin: -980.47%
• Return on Equity: -177.91%
• Return on Assets: -60.15%

Debt

• Debt-to-Equity Ratio: 2.08
• Current Ratio: 2.93
• Quick Ratio: 2.91

Sales & Book Value

• Annual Sales: $14 million
• Price / Sales: 89.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.91 per share
• Price / Book: 16.04

Miscellaneous

• Outstanding Shares: 85,490,000
• Free Float: 59,754,000
• Market Cap: $1.25 billion
• Optionable: Optionable
• Beta: -0.01